Icahn School of Medicine at Mount Sinai (ISMMS), New York, New York, USA.
Institute for HealthCare Delivery Science, Department of Population Health Science and Policy, ISMMS, New York, New York, USA.
Epilepsia. 2023 Oct;64(10):2725-2737. doi: 10.1111/epi.17715. Epub 2023 Jul 28.
Coronavirus disease 2019 (COVID-19) is associated with mortality in persons with comorbidities. The aim of this study was to evaluate in-hospital outcomes in patients with COVID-19 with and without epilepsy.
We conducted a retrospective study of patients with COVID-19 admitted to a multicenter health system between March 15, 2020, and May 17, 2021. Patients with epilepsy were identified using a validated International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)/ICD-10-CM case definition. Logistic regression models and Kaplan-Meier analyses were conducted for mortality and non-routine discharges (i.e., not discharged home). An ordinary least-squares regression model was fitted for length of stay (LOS).
We identified 9833 people with COVID-19 including 334 with epilepsy. On univariate analysis, people with epilepsy had significantly higher ventilator use (37.70% vs 14.30%, p < .001), intensive care unit (ICU) admissions (39.20% vs 17.70%, p < .001) mortality rate (29.60% vs 19.90%, p < .001), and longer LOS (12 days vs 7 days, p < .001). and fewer were discharged home (29.64% vs 57.37%, p < .001). On multivariate analysis, only non-routine discharge (adjusted odds ratio [aOR] 2.70, 95% confidence interval [CI] 2.00-3.70; p < .001) and LOS (32.50% longer, 95% CI 22.20%-43.60%; p < .001) were significantly different. Factors associated with higher odds of mortality in epilepsy were older age (aOR 1.05, 95% CI 1.03-1.08; p < .001), ventilator support (aOR 7.18, 95% CI 3.12-16.48; p < .001), and higher Charlson comorbidity index (CCI) (aOR 1.18, 95% CI 1.04-1.34; p = .010). In epilepsy, admissions between August and December 2020 or January and May 2021 were associated with a lower odds of non-routine discharge and decreased LOS compared to admissions between March and July 2020, but this difference was not statistically significant.
People with COVID-19 who had epilepsy had a higher odds of non-routine discharge and longer LOS but not higher mortality. Older age (≥65), ventilator use, and higher CCI were associated with COVID-19 mortality in epilepsy. This suggests that older adults with epilepsy and multimorbidity are more vulnerable than those without and should be monitored closely in the setting of COVID-19.
2019 年冠状病毒病(COVID-19)与合并症患者的死亡率有关。本研究的目的是评估 COVID-19 合并和不合并癫痫患者的住院治疗结局。
我们对 2020 年 3 月 15 日至 2021 年 5 月 17 日期间在一个多中心医疗系统住院的 COVID-19 患者进行了回顾性研究。使用经过验证的国际疾病分类,第九修订版,临床修正(ICD-9-CM)/国际疾病分类第 10 版临床修正(ICD-10-CM)病例定义来确定癫痫患者。进行逻辑回归模型和 Kaplan-Meier 分析以评估死亡率和非常规出院(即未出院回家)。拟合普通最小二乘回归模型以评估住院时间(LOS)。
我们确定了 9833 名 COVID-19 患者,其中 334 名患有癫痫。在单变量分析中,患有癫痫的患者呼吸机使用率(37.70% vs 14.30%,p <.001)、重症监护病房(ICU)入院率(39.20% vs 17.70%,p <.001)、死亡率(29.60% vs 19.90%,p <.001)和 LOS 更长(12 天 vs 7 天,p <.001),且出院回家的比例更低(29.64% vs 57.37%,p <.001)。多变量分析显示,仅非常规出院(调整后的优势比[aOR]2.70,95%置信区间[CI]2.00-3.70;p <.001)和 LOS(延长 32.50%,95% CI 22.20%-43.60%;p <.001)差异有统计学意义。癫痫患者死亡率较高的相关因素包括年龄较大(aOR 1.05,95% CI 1.03-1.08;p <.001)、呼吸机支持(aOR 7.18,95% CI 3.12-16.48;p <.001)和更高的 Charlson 合并症指数(CCI)(aOR 1.18,95% CI 1.04-1.34;p =.010)。在癫痫患者中,与 2020 年 3 月至 7 月的住院时间相比,2020 年 8 月至 12 月或 2021 年 1 月至 5 月的住院时间与非常规出院和 LOS 缩短的几率较低,但差异无统计学意义。
患有 COVID-19 的癫痫患者非常规出院和 LOS 较长的几率较高,但死亡率没有增加。年龄较大(≥65 岁)、使用呼吸机和更高的 CCI 与癫痫患者 COVID-19 的死亡率有关。这表明,患有癫痫和多种合并症的老年患者比没有这些疾病的患者更容易受到影响,在 COVID-19 流行期间应密切监测。